Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0929-z
Abstract: Sarilumab (Kevzara®), a monoclonal antibody against the interleukin-6 (IL-6) receptor, is approved in various countries, including the USA, those of the EU, and Japan, as a subcutaneous treatment administered every 2 weeks for moderately to severely… read more here.
Keywords: review moderate; sarilumab review; sarilumab; rheumatoid arthritis ... See more keywords
Dupilumab: A Review in Moderate to Severe Asthma
Sign Up to like & getrecommendations! Published in 2019 at "Drugs"
DOI: 10.1007/s40265-019-01221-x
Abstract: Dupilumab (Dupixent®) is a fully human monoclonal antibody against the interleukin (IL)-4 receptor α subunit of IL-4 and IL-4/IL-13 receptor complexes. IL-4 and IL-13 are key cytokines in driving type 2 inflammation, a dominant and… read more here.
Keywords: dupilumab review; severe asthma; asthma; review moderate ... See more keywords